The Phase III KOASTAL-1 study with Neumora’s lead asset navacaprant failed to meet its primary and secondary endpoint.

Drug manufacturers increased the list prices of at least 250 brand-name medications as of Jan. 1 as the future of the ...

States are channeling funds into overdose response equipment, drug identification tools and community recovery initiatives ...

The Royal Society of Chemistry’s (RSC’s) immediate past president, Gill Reid, is one of several members of the chemical ...

Star RMG Infrastructure Limited, established in 2001, continues to lead the infrastructure sector with cutting-edge projects ...

Veeda Group has unveiled a new logo and brand identity--Veeda Lifesciences--marking a key milestone in its journey. The new ...

The Role of Water for Injection (WFI) in Pharmaceutical ManufacturingWater for Injection (WFI) serves as a cornerstone of ...

Japan Airlines (JAL) is taking a significant leap forward in the logistics and healthcare sectors by incorporating drone ...

We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

It’s been another busy year in Indiana health care and life sciences, with headlines nearly every week announcing another ...

The healthcare sector has become a focal point for private equity firms, with investments increasing in response to growing ...